JP4651946B2 - 肺病態の治療および予防 - Google Patents

肺病態の治療および予防 Download PDF

Info

Publication number
JP4651946B2
JP4651946B2 JP2003587321A JP2003587321A JP4651946B2 JP 4651946 B2 JP4651946 B2 JP 4651946B2 JP 2003587321 A JP2003587321 A JP 2003587321A JP 2003587321 A JP2003587321 A JP 2003587321A JP 4651946 B2 JP4651946 B2 JP 4651946B2
Authority
JP
Japan
Prior art keywords
composition
lung
pulmonary
inhibitor
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2003587321A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005529885A (ja
JP2005529885A5 (enExample
Inventor
チャールズ ジー． コックレーン，
Original Assignee
ザ スクリプス リサーチ インスティテュート
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ スクリプス リサーチ インスティテュート filed Critical ザ スクリプス リサーチ インスティテュート
Publication of JP2005529885A publication Critical patent/JP2005529885A/ja
Publication of JP2005529885A5 publication Critical patent/JP2005529885A5/ja
Application granted granted Critical
Publication of JP4651946B2 publication Critical patent/JP4651946B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/785—Alveolar surfactant peptides; Pulmonary surfactant peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2003587321A 2002-04-25 2003-04-25 肺病態の治療および予防 Expired - Fee Related JP4651946B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37596802P 2002-04-25 2002-04-25
PCT/US2003/012731 WO2003090682A2 (en) 2002-04-25 2003-04-25 Treatment and prevention of pulmonary conditions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010224369A Division JP2011001383A (ja) 2002-04-25 2010-10-01 肺病態の治療および予防

Publications (3)

Publication Number Publication Date
JP2005529885A JP2005529885A (ja) 2005-10-06
JP2005529885A5 JP2005529885A5 (enExample) 2010-12-09
JP4651946B2 true JP4651946B2 (ja) 2011-03-16

Family

ID=29270737

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2003587321A Expired - Fee Related JP4651946B2 (ja) 2002-04-25 2003-04-25 肺病態の治療および予防
JP2010224369A Withdrawn JP2011001383A (ja) 2002-04-25 2010-10-01 肺病態の治療および予防

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010224369A Withdrawn JP2011001383A (ja) 2002-04-25 2010-10-01 肺病態の治療および予防

Country Status (13)

Country Link
US (2) US7863241B2 (enExample)
EP (1) EP1558273B1 (enExample)
JP (2) JP4651946B2 (enExample)
KR (2) KR101036058B1 (enExample)
CN (1) CN1838964A (enExample)
AT (1) ATE520411T1 (enExample)
AU (1) AU2003223718B2 (enExample)
CA (1) CA2483102C (enExample)
IL (2) IL164795A0 (enExample)
MX (1) MXPA04010560A (enExample)
NZ (1) NZ536796A (enExample)
WO (1) WO2003090682A2 (enExample)
ZA (1) ZA200408573B (enExample)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ536796A (en) 2002-04-25 2007-03-30 Scripps Research Inst Treatment and prevention of pulmonary conditions comprising at least one lung surfactant polypeptide and at least one protease inhibitor, lipase inhibitor or an anti-oxidant
AU2004296206A1 (en) * 2003-12-04 2005-06-23 The Scripps Research Institute Treatment and preventions of asthma
WO2005073246A2 (en) * 2004-01-20 2005-08-11 Discovery Laboratories, Inc. Method for preparing kl4 lung surfactant
JP4160615B2 (ja) * 2004-03-11 2008-10-01 レドックス・バイオサイエンス株式会社 プロテアーゼ阻害剤
US7608579B2 (en) 2004-06-16 2009-10-27 Pneumrx, Inc. Lung volume reduction using glue compositions
US7678767B2 (en) 2004-06-16 2010-03-16 Pneumrx, Inc. Glue compositions for lung volume reduction
US20050281799A1 (en) 2004-06-16 2005-12-22 Glen Gong Targeting damaged lung tissue using compositions
US7553810B2 (en) 2004-06-16 2009-06-30 Pneumrx, Inc. Lung volume reduction using glue composition
CA2570261C (en) 2004-07-08 2014-06-10 Pneumrx, Inc. Pleural effusion treatment device, method and material
MX2007002903A (es) * 2004-09-10 2007-07-11 Pharmaorigin Aps Metodos para el tratamiento de hemoptisis o hemorragias traqueales, bronquiales o alveolares, locales.
US8337815B2 (en) * 2004-12-23 2012-12-25 Discovery Laboratories, Inc. Pulmonary surfactant formulations
WO2006071102A1 (en) * 2004-12-30 2006-07-06 Dobeel Co., Ltd. Spray-dried composition containing collectin family proteins or variants therof and process for preparing the same
GB0510463D0 (en) * 2005-05-23 2005-06-29 Britania Pharmaceuticals Ltd Improvements in or relating to organic materials
ZA200800251B (en) * 2005-06-24 2009-04-29 Drugrecure Aps Airway administration of tissue factor pathway inhibitor in inflammatory conditions affecting the respiratory track
WO2007005672A2 (en) * 2005-06-30 2007-01-11 The Scripps Research Institute Treatment and prevention of respiratory diseases and conditions
CA2718130A1 (en) 2007-03-29 2008-10-09 National Jewish Health Surfactant lipids, compositions thereof, and uses thereof
EP1997502A1 (en) * 2007-06-01 2008-12-03 CHIESI FARMACEUTICI S.p.A. Reconstituted surfactants having improved properties
AU2008259768B2 (en) * 2007-06-05 2013-08-29 Paka Pulmonary Pharmaceuticals, Inc. Compositions for delivering medicaments into the lungs, uses thereof
EP2227085A4 (en) * 2007-12-06 2013-10-09 Berg Pharma Llc INGREDIBLE COMPOSITIONS WITH INCREASED BIOLOGICAL AVAILABILITY
GB0724772D0 (en) 2007-12-19 2008-01-30 Ucl Business Plc Carrier
AU2009324637B2 (en) * 2008-12-10 2016-09-08 Paka Pulmonary Pharmaceuticals, Inc. Methods and compositions for delivery of medicaments to the lungs
CN102300582A (zh) 2009-01-30 2011-12-28 阿尔法贝塔公司 用于治疗阿尔茨海默病的化合物和方法
US8434479B2 (en) * 2009-02-27 2013-05-07 Covidien Lp Flow rate compensation for transient thermal response of hot-wire anemometers
JP5622728B2 (ja) * 2009-08-06 2014-11-12 一般財団法人化学及血清療法研究所 咳嗽抑制効果を持つ血漿タンパク質
EP2308489B1 (en) * 2009-10-05 2014-01-01 Nutri-Fit GmbH & Co. KG Compositions for use in treating or preventing metabolic stress-induced lung injury and methods for increasing physical capacity of mammalian livestock
CN102655876B (zh) * 2009-11-03 2015-07-15 基立福疗法公司 α-1蛋白酶抑制剂组合物、方法和试剂盒
BR112012012460B1 (pt) 2009-11-24 2020-06-23 Grifols Therapeutics Inc. Método de liofilização de uma composição
GB201003559D0 (en) * 2010-03-03 2010-04-21 Proteo Biotech Ag Novel use of elafin
BR112012022916B1 (pt) 2010-03-12 2021-11-09 Berg Llc Formulações intravenosas de coenzima q10 (coq10), bem como método de preparação e uso da mesma
AU2010356144B2 (en) 2010-06-24 2015-06-04 Alphabeta Ab Compound and method for treatment of Alzheimer's disease and familial dementia
CN101897720B (zh) * 2010-07-27 2015-09-09 北京华禧联合科技发展有限公司 一种治疗呼吸道疾病的药物组合物
CA2854437A1 (en) * 2010-11-04 2012-05-10 The Board Of Regents Of The University Of Oklahoma Peptide compositions that downregulate tlr-4 signaling pathway and methods of producing and using same
US20130184202A1 (en) * 2011-02-08 2013-07-18 Changjiang Guo Peptide Inhibitors and Methods of Use Thereof
US9522170B2 (en) 2011-04-05 2016-12-20 Alphabeta Ab Methods of screening compounds for the fibril formation of Aβ peptides based on a decreased trimer/monomer ratio of a chaperone protein
US9890200B2 (en) 2011-04-12 2018-02-13 Moerae Matrix, Inc. Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
CN108014340A (zh) * 2011-04-12 2018-05-11 莫伊莱麦屈克斯公司 用于预防或治疗以成纤维细胞异常增殖及细胞外基质沉积为特征的疾病的组合物和方法
US20140239525A1 (en) 2011-06-17 2014-08-28 Board Of Regents, University Of Texas System Inhalable pharmaceutical compositions
US9089657B2 (en) 2011-10-31 2015-07-28 Covidien Lp Methods and systems for gating user initiated increases in oxygen concentration during ventilation
WO2013188016A2 (en) * 2012-05-04 2013-12-19 Discovery Laboratories, Inc. Surfactant therapy for exposure to ionizing radiation
AU2014324093A1 (en) * 2013-09-18 2016-04-28 James Cook University Anti-inflammatory proteins and methods of use
CN105745223A (zh) 2013-09-18 2016-07-06 詹姆斯库克大学 修饰的抗炎蛋白及使用方法
WO2015061412A1 (en) * 2013-10-22 2015-04-30 The Scripps Research Institute Methods and compositions for promoting bronchioli dilatation
EP3185892B1 (en) * 2014-08-26 2020-02-12 Proteo Biotech AG Use of elafin for disorders associated with elastase independent increase in troponin
US10568846B2 (en) 2015-04-27 2020-02-25 Omniactive Health Technologies Limited Betacryptoxanthin compositions, processes for preparation and uses thereof
US10239847B1 (en) 2016-03-03 2019-03-26 Cellactin Method for 2-oxothiazolidine-4-carboxylic acid for cellular glutathione
CA3036553A1 (en) * 2016-09-13 2018-03-22 Prothera Biologics, Inc. Methods for treating pulmonary disease using inter-alpha inhibitor proteins
AU2018241248B2 (en) * 2017-03-31 2025-01-23 Ena Respiratory Pty Ltd Treatment of respiratory infection with a TLR2 agonist
MX2020006634A (es) * 2017-12-21 2021-01-15 Civitas Therapeutics Inc Formulaciones de surfactantes para inhalacion.
WO2019202326A1 (en) * 2018-04-17 2019-10-24 Lamellar Biomedical Limited Antifibrotic composition
CN112703009B (zh) * 2018-08-17 2024-06-11 宾夕法尼亚大学董事会 治疗急性肺损伤的组合物和方法
JP7577335B2 (ja) 2018-10-19 2024-11-05 オハイオ・ステイト・イノベーション・ファウンデーション 肺炎症治療用のナノキャリア
EP3869985A4 (en) * 2018-10-23 2022-07-27 George Edward Hoag COMPOSITION AND METHOD OF TREATMENT OF THE LUNGS
EP3873453A4 (en) * 2018-10-30 2022-08-03 University of Florida Research Foundation, Incorporated AMINO ACID COMPOSITIONS AND METHODS OF TREATMENT OF CF
JP2022542519A (ja) * 2019-08-01 2022-10-04 サープラス テクノロジー エルエルシー 酸化耐性セルピン
KR102276935B1 (ko) * 2020-02-06 2021-07-12 한양대학교 산학협력단 신규한 비올라크산틴 고생산 클로렐라 불가리스 균주 및 이로부터 비올라크산틴을 생산하는 방법
US20230135877A1 (en) * 2020-04-08 2023-05-04 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for treating and preventing lung disease
CN115245559B (zh) * 2021-04-25 2026-05-01 上海萨美细胞技术有限公司 一种用于治疗肺损伤的药物
WO2024097169A1 (en) * 2022-11-01 2024-05-10 National Jewish Health Treatment of coronavirus infections with antimicrobial phospholipid compositions
CN116421704A (zh) * 2023-02-20 2023-07-14 成都佩德生物医药有限公司 多肽pd-dp-005在制备治疗肺部疾病药物中的应用及其药物
CN120000688B (zh) * 2025-04-16 2025-08-05 山东杰凯生物科技有限公司 基于干细胞外囊泡的雾化吸入组合物及其制备方法、应用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57144224A (en) * 1981-03-02 1982-09-06 Mochida Pharmaceut Co Ltd Remedy for respiratory dieseases
US4916117A (en) * 1986-12-24 1990-04-10 John Lezdey Treatment of inflammation using alpha 1-antichymotrypsin
US5260273A (en) * 1988-01-06 1993-11-09 The Scripps Research Institute Pulmonary surfactant protein and related polypeptide
US5164369A (en) 1988-01-06 1992-11-17 The Scripps Research Institute Pulmonary surfactant protein and related polypeptide
US6013619A (en) * 1988-01-06 2000-01-11 The Scripps Research Institute Pulmonary surfactants and therapeutic uses, including pulmonary lavage
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US5707634A (en) 1988-10-05 1998-01-13 Pharmacia & Upjohn Company Finely divided solid crystalline powders via precipitation into an anti-solvent
NO177716C (no) * 1989-06-09 1995-11-08 Zeneca Ltd Fremgangsmåte for fremstilling av terapeutisk aktive polypeptider, DNA-sekvens, ekspresjonsvektor og antistoff
AU638474B2 (en) * 1989-07-11 1993-07-01 Genentech Inc. Surfactant compositions and methods
US5993805A (en) 1991-04-10 1999-11-30 Quadrant Healthcare (Uk) Limited Spray-dried microparticles and their use as therapeutic vehicles
US5272252A (en) * 1991-11-04 1993-12-21 Merrell Dow Pharmaceuticals Inc. Synthetic lung surfactant having antioxidant properties
AU664112B2 (en) * 1992-07-31 1995-11-02 Merrell Dow Pharmaceuticals Inc. Synthetic peptide lung surfactants having covalently bonded antioxidants
US5734014A (en) * 1992-08-11 1998-03-31 Tsumura & Co. Elafin derivative
WO1994008599A1 (en) 1992-10-14 1994-04-28 The Regents Of The University Of Colorado Ion-pairing of drugs for improved efficacy and delivery
US5301644A (en) 1993-06-16 1994-04-12 Kohler Co. Fuel shut-off mechanism for internal combustion engines
US5961970A (en) 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
AU690986B2 (en) * 1994-06-02 1998-05-07 Merrell Pharmaceuticals Inc. Perfluoroalkyl ketone inhibitors of elastase and processes for making the same
GB9413202D0 (en) 1994-06-30 1994-08-24 Univ Bradford Method and apparatus for the formation of particles
US5878912A (en) 1995-12-26 1999-03-09 Stein; Myron Duct disinfecting method and apparatus
US5874029A (en) 1996-10-09 1999-02-23 The University Of Kansas Methods for particle micronization and nanonization by recrystallization from organic solutions sprayed into a compressed antisolvent
US5833891A (en) 1996-10-09 1998-11-10 The University Of Kansas Methods for a particle precipitation and coating using near-critical and supercritical antisolvents
US5780440A (en) * 1996-06-17 1998-07-14 Protease Sciences Inc. Treatment of pulmonary disease with protease inhibitors
US6001336A (en) 1996-12-31 1999-12-14 Inhale Therapeutic Systems Processes for spray drying aqueous suspensions of hydrophobic drugs and compositions thereof
US6051257A (en) 1997-02-24 2000-04-18 Superior Micropowders, Llc Powder batch of pharmaceutically-active particles and methods for making same
JP3796340B2 (ja) * 1997-11-18 2006-07-12 株式会社ノエビア セリンプロテアーゼ阻害剤
JPH11147832A (ja) * 1997-11-18 1999-06-02 Noevir Co Ltd 好中球エラスターゼ阻害剤
US6284282B1 (en) 1998-04-29 2001-09-04 Genentech, Inc. Method of spray freeze drying proteins for pharmaceutical administration
US5883084A (en) * 1998-06-08 1999-03-16 Clarion Pharmaceuticals Inc. Treatment of respiratory diseases utilizing α-tocopheryl-phosphocholine
US6223455B1 (en) 1999-05-03 2001-05-01 Acusphere, Inc. Spray drying apparatus and methods of use
WO2001019392A1 (en) 1999-09-16 2001-03-22 Byk Gulden Lomberg Chemische Fabrik Gmbh Combination of c1-inh and lung surfactant for the treatment of respiratory disorders
CN1310679C (zh) * 1999-12-28 2007-04-18 诺瓦提斯公司 获得持续的转基因表达的方法
WO2001049315A1 (en) * 2000-01-06 2001-07-12 Eli Lilly And Company Combination therapy for the treatment of inflammatory and respiratory diseases
NZ536796A (en) 2002-04-25 2007-03-30 Scripps Research Inst Treatment and prevention of pulmonary conditions comprising at least one lung surfactant polypeptide and at least one protease inhibitor, lipase inhibitor or an anti-oxidant
US6819898B2 (en) * 2002-11-22 2004-11-16 Kabushiki Kaisha Toshiba Image forming apparatus including stopping member and backstop member to stop rotation of revolver type developing unit

Also Published As

Publication number Publication date
CN1838964A (zh) 2006-09-27
JP2005529885A (ja) 2005-10-06
AU2003223718A1 (en) 2003-11-10
EP1558273A4 (en) 2008-07-16
CA2483102C (en) 2013-06-18
US20120189602A1 (en) 2012-07-26
ATE520411T1 (de) 2011-09-15
US20050070477A1 (en) 2005-03-31
JP2011001383A (ja) 2011-01-06
KR20110017465A (ko) 2011-02-21
CA2483102A1 (en) 2003-11-06
NZ536796A (en) 2007-03-30
KR20050019073A (ko) 2005-02-28
US7863241B2 (en) 2011-01-04
WO2003090682A2 (en) 2003-11-06
IL164795A (en) 2011-02-28
KR101036058B1 (ko) 2011-05-19
MXPA04010560A (es) 2005-08-15
ZA200408573B (en) 2006-03-29
AU2003223718C1 (en) 2003-11-10
WO2003090682A3 (en) 2004-09-16
EP1558273A2 (en) 2005-08-03
EP1558273B1 (en) 2011-08-17
AU2003223718B2 (en) 2007-08-16
IL164795A0 (en) 2005-12-18

Similar Documents

Publication Publication Date Title
AU2003223718C1 (en) Treatment and prevention of pulmonary conditions
JP2005529885A5 (enExample)
AU738298B2 (en) Secretory leukocyte protease inhibitor dry powder pharmaceutical compositions
US20070129297A1 (en) Treatment and prevention of asthma
JP2013177422A (ja) サーファクタント処置療法
JP2010505937A (ja) 改善された性質を有する再構成サーファクタント
WO2007005672A2 (en) Treatment and prevention of respiratory diseases and conditions
EP1140150B1 (en) Method for accelerating the rate of mucociliary clearance by using a kunitz-type serine protease inhibitor
RU2496516C2 (ru) Введение в дыхательные пути ингибитора тканевого фактора при воспалительных состояниях, поражающих дыхательные пути
WO2015061412A1 (en) Methods and compositions for promoting bronchioli dilatation

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060316

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060316

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090707

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20091005

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091013

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20091105

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100601

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20101001

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20101027

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20101119

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20101215

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20131224

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20131224

Year of fee payment: 3

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20131224

Year of fee payment: 3

R370 Written measure of declining of transfer procedure

Free format text: JAPANESE INTERMEDIATE CODE: R370

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees